基于捕获的靶向超深度测序在配对组织与血浆样本中揭示晚期肺癌亚克隆ctDNA释放能力差异
本研究对40对晚期肺癌患者配对活检组织与血浆样本进行基于捕获的LungPlasma panel(覆盖168个基因关键外显子与内含子)深度测序,以组织突变作为参考,评估亚克隆ctDNA释放效率。结果显示总体变异水平敏感度为87.2%,七个关键可靶向基因敏感度为96.2%;携带驱动突变的亚克隆平均NRAFS为0.877,其他突变为0.658,细胞周期通路相关基因突变NRAFS为0.480(p=0.07)。作者认为携带驱动突变的亚克隆更易释放DNA,捕获测序的定量能力为其临床常规应用铺平道路。
要点
- 配对组织与血浆捕获测序总体变异水平敏感度为87.2%。
- 七个关键可靶向基因的变异水平敏感度为96.2%。
- 驱动突变亚克隆平均NRAFS 0.877,其他突变0.658。
核心结论
- 携带驱动突变的亚克隆更易释放DNA;捕获测序的定量能力为其临床常规应用铺平道路。
研究设计与样本
- 研究收集40对晚期肺癌患者配对的活检组织与血浆样本,采用LungPlasma panel进行基于捕获的测序,该panel覆盖168个基因的关键外显子与内含子。
- 研究推导归一化相对等位基因分数评分(NRAFS)以反映ctDNA释放效率,并以活检样本中检测到的突变为参考进行比较。
主要发现
- 以活检样本突变作为参考,总体变异水平敏感度为87.2%,包括单核苷酸变异、插入或缺失及基因融合。
- 七个最关键且可靶向基因的变异水平敏感度为96.2%。
- 携带七个可靶向基因突变的亚克隆平均NRAFS为0.877,其他突变平均NRAFS为0.658。
- 细胞周期通路相关四个基因的突变NRAFS为0.480,与其他两组比较p=0.07。
关键数值与推荐
- 总体变异水平敏感度87.2%。
- 七个最关键且可靶向基因的变异水平敏感度96.2%。
- 七个可靶向基因突变亚克隆平均NRAFS 0.877,其他突变平均NRAFS 0.658。
- 细胞周期通路相关四个基因突变NRAFS 0.480,与其他两组比较p=0.07。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Circulating tumor DNA (ctDNA), which represents an unbiased way to assess tumor genetic profile noninvasively, facilitates studying intratumor heterogeneity. Although intratumor heterogeneity has been elucidated substantially in a few cancer types, including NSCLC, how it influences the ability of tumor cells harboring different genetic abnormalities in releasing their DNA remains elusive. We designed a capture-based panel targeting NSCLC to detect and quantify genetic alterations from plasma samples by using deep sequencing. By applying the panel to paired biopsy and plasma samples, we imputed and compared the ctDNA-releasing efficiency in subclones harboring distinct genetic variants. METHODS: We collected 40 pairs of matched biopsy and plasma samples from patients with advanced lung cancer and applied capture-based sequencing using our LungPlasma panel, which consists of critical exons and introns of 168 genes. We derived a normalized relative allelic fraction score (NRAFS) to reflect ctDNA-releasing efficiency. RESULTS: By using mutations detected in biopsy samples as a reference, we achieved 87.2% by-variant sensitivity, including for single-nucleotide variants, insertions or deletions, and gene fusions. Furthermore, the by-variant sensitivity for the seven most critical and actionable genes was 96.2%. The average NRAFS for subclones carrying mutations from seven actionable genes was 0.877; in contrast, the average NRAFS for other mutations was 0.658. Mutations from four genes involved in cell cycle pathways had a particularly low NRAFS (0.480) compared with the other two groups (p = 0.07). CONCLUSIONS: We have demonstrated that subclones carrying driver mutations are more prone to release DNA. We have also demonstrated the quantitative ability of capture-based sequencing, paving its way for routine utilization in clinical settings.
引用
- Mao X, Zhang Z, Zheng X, et al. Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer. J Thorac Oncol. 2016. PMID: 28007624. doi:10.1016/j.jtho.2016.11.2235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。